A double blind, placebo-controlled study that looked into the potential effectiveness of topical fluridil for treating male androgenetic alopecia, showing increased anagen to telogenratios with no reported side effects on libido or sexual performance.
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
A user is experiencing rapid hair loss and has been diagnosed with telogen effluvium by multiple dermatologists, but doubts the diagnosis due to the severity and speed of the hair loss. They are considering various treatments like spironolactone, estradiol, and possibly finasteride, while also exploring the possibility of hormonal imbalances or autoimmune issues.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.